

Performance review for FreeStyle Libre Glucose Monitoring Systems

Submission date 13/05/2021	Recruitment status Recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 28/06/2021	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 25/06/2021	Condition category Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Diabetes is a lifelong condition where the amount of sugar in the blood is too high. The aim of this study is to collect glucose data using the FreeStyle Libre Glucose Monitoring System from adults.

Who can participate?

Anyone aged 18 without diabetes or with type 1 or type 2 diabetes

What does the study involve?

Participants will wear up to four sensors for up to 14 days, after which sensors will be removed, and data uploaded. Each study event aims to recruit between 18 and 72 participants. Once a study event is complete another one commences, on a continuing basis. Each participant is in the study for up to 15 days.

What are the possible benefits & risks of participating?

There is no direct benefit to the participant by taking part in this study. The only risks associated with the study are from obtaining capillary blood samples, these are small but could include pain, bruising, local infection and fainting.

Where is the study run from?

Abbott Diabetes Care (UK)

When is the study starting and how long is it expected to run for?

May 2020 to December 2031

Who is funding the study?

Abbott Diabetes Care (UK)

Who is the main contact?

Dr Pamela Reid

Contact information

Type(s)

Public

Contact name

Dr Pamela Reid

Contact details

Range Road

Witney

United Kingdom

OX29 0YL

+44 (0)1993 863024

ADC.Clinical.Affairs.UK@abbott.com

Additional identifiers**Clinical Trials Information System (CTIS)**

Nil known

Integrated Research Application System (IRAS)

292446

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

ADC-UK-PMS-20048, IRAS 292446

Study information**Scientific Title**

Sensor accuracy performance review for FreeStyle Libre Glucose Monitoring Systems

Study objectives

Accuracy of FreeStyle Libre Glucose Monitoring Systems compared to capillary fingerstick blood glucose values using the consensus error grid.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 12/04/2021, West Midlands - South Birmingham Research Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, UK; +44 (0)207 104 8345, +44 (0)207 104 8107, +44 (0)207 104 8388; southbirmingham.rec@hra.nhs.uk), REC ref: 21/WM/0064

Study design

Prospective single-arm single-centre study

Primary study design

Observational

Study type(s)

Other

Health condition(s) or problem(s) studied

Diabetes mellitus

Interventions

Participants will wear up to four FreeStyle Libre Sensors for up to 14 days. There is no follow-up period unless the participant experiences an unanticipated adverse device effect (UADE).

Intervention Type

Device

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

FreeStyle Libre Sensors

Primary outcome(s)

Accuracy of the FreeStyle Libre Glucose Monitoring Systems compared to capillary fingerstick blood glucose values (FreeStyle Optium blood glucose test strips) using the consensus error grid at the end of the sensor wear period

Key secondary outcome(s)

There are no secondary outcome measures

Completion date

31/12/2031

Eligibility

Key inclusion criteria

1. Aged 18 years or over
2. Has type 1 or type 2 diabetes or has not been diagnosed as having diabetes
3. Be willing and able to test their blood glucose levels at least four times a day

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Has another form of diabetes e.g. maturity-onset diabetes of the young (MODY)
2. Have a known (or suspected) allergy to medical grade adhesive
3. Have a skin abnormality at the application sites
4. Have a pacemaker or any other neurostimulators
5. Have concomitant medical condition which in the participant's opinion could interfere with the study or present a risk to their safety or welfare, or that of the study team

Date of first enrolment

01/05/2021

Date of final enrolment

16/12/2031

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

Abbott Diabetes Care Ltd

Range Road

witney

United Kingdom

OX29 0YL

Sponsor information**Organisation**

Abbott (United Kingdom)

ROR

<https://ror.org/03wnay029>

Funder(s)**Funder type**

Industry

Funder Name

Abbott Diabetes Care

Alternative Name(s)**Funding Body Type**

Private sector organisation

Funding Body Subtype

For-profit companies (industry)

Location

United States of America

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available due to lack of consent to share. All data will be held by Abbott Diabetes Care and used as part of a post-market surveillance program.

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No